Betaxolol is a racemic mixture and beta-adrenergic receptor inhibitor used to treat patients with chronic open-angle glaucoma or ocular hypertension. It was first approved by the U.S. Food and Drug Administration (FDA) in 1989, as an oral tablet. Betaxolol is used either alone or in combination with other medicines to lower down the pressure within the heart or eye. In the heart, Betaxolol decreases the cardiac contractility and rate selectively by actively binding and blocking beta-1 adrenergic receptors. This leads to reduction in cardiac output and lowers blood pressure. Topical applications in the eye reduces aqueous humor secretion and lowers the Intraocular Pressure (IOP) resulting in low risk of optic nerve damage and loss of vision in patients. Betaxolol further inhibits the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels.
Browse Full Report: https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781
Betaxolol Market Drivers
Increasing prevalence of glaucoma worldwide is propelling growth of the market. According to the Glaucoma research Foundation, glaucoma is the leading cause of irreversible blindness worldwide. Around 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be suffering from glaucoma worldwide, in 2013. Furthermore, according to the American Academy of Ophthalmology, the prevalence of glaucoma is high in Africa and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery. – 50 patients per million of the population. Although treatment available for pulmonary arterial hypertension is limited, beta-adrenergic receptor inhibitor, Prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors are available to decrease symptoms, slow down disease progression, and improve the quality of life.
Betaxolol Market Restraint
Stringent regulatory approvals to ensure the safety of drugs and patent expiry of betaxolol drugs such as Betoptic S and Betoptic Liq, are major challenge for growth of the market, as the generic versions of these drugs are sold at 70% to 80% lower prices as compared to the branded drugs.
The market players operating in betaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1781
Betaxolol Market Taxonomy: By Dosage Form: Tablets, Suspension,. By Disease Indication: Glaucoma, Ocular Hypertension,. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]